MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.945
-0.135
-3.31%
Opening 13:04 07/06 EDT
OPEN
4.040
PREV CLOSE
4.080
HIGH
4.180
LOW
3.750
VOLUME
141.40K
TURNOVER
340.38K
52 WEEK HIGH
38.88
52 WEEK LOW
3.258
MARKET CAP
23.19M
P/E (TTM)
-4.8251
1D
5D
1M
3M
1Y
5Y
Abeona crashes 21% as reverse stock split takes effect
Nano-cap clinical stage biotech Abeona Therapeutics (NASDAQ:ABEO</a...
Seekingalpha · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 1d ago
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Zacks · 06/24 14:08
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Zacks · 06/13 17:27
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
Zacks · 06/10 19:30
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investor Place · 06/10 11:27
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Zacks · 06/08 17:21
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
Zacks · 06/06 18:04
More
No Data
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABEO stock price target is 58.33 with a high estimate of 100.00 and a low estimate of 25.00.
High100.00
Average58.33
Low25.00
Current 3.800
EPS
Actual
Estimate
-3.20-2.40-1.60-0.80
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 11.55M
% Owned: 7.86%
Shares Outstanding: 5.88M
TypeInstitutionsShares
Increased
8
169.62K
New
9
14.13K
Decreased
16
462.21K
Sold Out
9
53.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.15%
Pharmaceuticals & Medical Research
+0.36%
Key Executives
Chairman/Director
Michael Amoroso
President/Chief Executive Officer/Director
Vishwas Seshadri
Chief Financial Officer/Chief Accounting Officer
Joseph Vazzano
General Counsel
Brendan O Malley
Director
Christine Silverstein
Independent Director
Leila Alland
Independent Director
Mark Alvino
Independent Director
Faith Charles
Independent Director
Paul Mann
Independent Director
Todd Wider
Independent Director
Donald Wuchterl
No Data
No Data
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) and ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM Capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs. It is applying AIM Capsid Technology to develop in-vivo gene therapies.

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.